Form 4 for TNGX Tango Therapeutics, Inc.
Accepted 2026-01-12 00:00:00 ET · period of report 2026-01-08 · accession 0001193125-26-009663 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-12 | 2026-01-08 | TNGX | Peters Malte | Pres, CEO, Dir | A - Grant | $0.00 | +350.0K | 367.5K | +2,000% | $0 |
| D | 2026-01-12 | 2026-01-08 | TNGX | Peters Malte | Pres, CEO, Dir | A - Grant | $0.00 | +1.65M | 1.65M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-08 | A | A | 350,000 | $0.00 | 367,500 | D | — | — | (F1) These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-01-08 | A | A | 1,650,000 | $0.00 | 1,650,000 | D | $11.06 · — to 2036-01-08 | 1,650,000 Common Stock | (F2) This option shall vest and become exercisable over a four-year period, with 25% vesting on January 8, 2027 and the remaining option shares vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |